ReviewEuropean journal of neurology2025
The Effects of Disease-Modifying Therapies on Optic Nerve Degeneration in Multiple Sclerosis.
Review in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Fifteen-Year Longitudinal Changes in Peripapillary Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis.Journal of clinical medicine · 2026Article
- Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis.Journal of neurology · 2026Observational
- Retinal nerve fiber layer thinning in multiple sclerosis: clinical implications, cognitive associations, and effects of disease-modifying therapies.Journal of neurology · 2025Article
- Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL) thinning are used as markers of subclinical retinal degeneration to evaluate the effect of disease-modifying therapies (DMTs) on disease progression in clinical trials of multiple sclerosis (MS). This study aimed to assess the available evidence regarding the effects of DMTs on retinal thinning in people with MS.
methodsDatabases were searched for studies reporting longitudinal optical coherence tomography (OCT)-derived annualized RNFL and GCIPL thinning in patients receiving DMTs treatment. The standardized mean differences (Hedges g) of RNFL and GCIPL thickness between the baseline and follow-up were used as the primary effect size measure. DMTs were divided into moderate (M-DMTs) and high (H-DMTs) efficacy therapies.
resultsTwenty-one studies including 2158 patients and 3685 eyes were included. Overall, significant annualized RNFL (g = -0.6715, p = 0.0077) and GCIPL (g = -0.31, p < 0.0001) thinning was observed at follow-up compared with baseline. Annualized RNFL thinning was only significant in the M-DMTs group (g = -0.6992, p = 0.0243). Annualized GCIPL thinning was significant in both M-DMTs (g = -0.38, p = 0.0006) and H-DMTs group (g = -0.19, p < 0.0001) but was significantly greater in the M-DMTs group compared with the H-DMTs group (g = -0.20, p = 0.0017). There was no difference in annualized GCIPL or RNFL thinning between RRMS and PMS, or between RRMS with and without ON history.
conclusionsHigh-DMTs are more effective in reducing longitudinal thinning of RNFL and GCIPL compared with M-DMTs. GCIPL thinning could serve as a sensitive predictor for the surveillance of optic nerve degeneration and the assessment of DMT efficacy for both RRMS and PMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.